Who We Are
We are a privately held medical device company developing a novel, rapid-acting brain stimulation technology designed to treat people suffering from major depressive disorder (MDD) who have not responded to existing treatments.
Our Mission
RESTORING MENTAL HEALTH.
Depression is caused by identifiable changes in brain networks.
We can restore healthy neural activity and relieve symptoms of depression.
What We Do
Breakthrough technology. Advanced imaging, individualized targeting, and novel stimulation patterns yield a new approach to personalized neurostimulation for people with treatment-resistant depression.
Leadership
Christian Gormsen
President and CEO
Member, Board of Directors
Over two decades of operational leadership experience across diverse continents and industries, most recently as president and CEO of Eargo, a medical device developer of innovative hearing aids. Previously an executive at GN Group, a global leader in intelligent audio solutions. Early career in investment banking before transitioning to McKinsey & Company.
JoLynn M. Short
Head of Commercialization
17 years’ experience designing, leading and scaling sales initiatives throughout the U.S. Previously VP of Strategy and Growth, Area VP, Central U.S, and Senior Director of Strategic Accounts, U.S. at iRhythm Technologies. Over 10 years’ experience leading high-performance commercial teams and generating significant growth in key metrics, including revenue, operating income and productivity.
Sarah Keenan
Head of Operations
15+ year career specializing in start-up commercialization for medical device companies. Previously Vice President, Commercial Enablement at iRhythm Technologies. Additional start-up experience in sales and training for CardioDx and ThermoFishcer Scientific, now PhadiaAB, Merz Pharmaceuticals, and Schering-Plough.
Huyen Duong
Head of Clinical, Quality and Regulatory
Over 20 years of experience in medical quality assurance, regulatory and clinical affairs. Previously VP of Regulatory, Quality and Clinical Affairs at Nesos Corp., Senior Director of Regulatory Affairs and Clinical at Nevro Corp., and Director of Regulatory Affairs at Boston Neuromodulation.
Leslie Stephens
Head of Reimbursement
20+ years’ experience in market access and reimbursement, marketing, and market development in the medical device industry. Previously EVP of Marketing at Elixir Medical and VP of Market Access at Heartflow; held multiple leadership positions at Abbott Vascular in Market Access and Marketing.
Investors
Heath Lukatch
PhD
Chairman of the Board – Magnus Medical
Founder and Managing Partner – Red Tree Venture Capital
Previously Partner, Managing Director, and Life Sciences Investment Team Leader in TPG’s Biotech, Growth and RISE platforms; co-founder and Partner at Novo Ventures’ San Francisco office; Managing Director at Piper Jaffray Ventures; co-founder and CEO of AutoMate Scientific. Led multiple investments with successful exits, including Amira, AnaptysBio, Cianna Medical, Engage Therapeutics, Elevation Pharma, Flexion, FoldRx, Spinifex and Vaxcyte. Currently chairman of publicly traded companies Inogen and Satsuma Pharmaceuticals. McKinsey alumnus with PhD in neuroscience from Stanford.
Andrew Firlik
MD
Co-Founder and Managing Partner – JAZZ Venture Partners
Deep experience in venture capital investment, company building, technology development, and neurosurgery. Previous partner at Flare Capital Partners and principal at Canaan Partners; founder and key inventor of Northstar Neuroscience (IPO in 2006, subsequently acquired by St. Jude Medical); was chairman of IntElect Medical (acquired by Boston Scientific). Led investments with successful exit and held board seats at BridgePoint Medical, Explorys, Eyefluence, Visiogen, and more. Board-certified neurosurgeon with over 50 medical articles and numerous patents.